Payment overview · 2025
General Payments
$144.28
7 reported records · 5 companies
Healthcare provider profile · identity verified
Saadia Qasim, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELKHART, IN · NPI 1164781480
Verified facts
What the public records show
CMS Open Payments records show Saadia Qasim, M.D. received $144.28 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 46.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.29 | 46.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.12 | 16.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 13.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.14 | 12.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.88 | 11.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.43 | 6 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
110 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1047 | 294 |
| Amlodipine Besylate | Amlodipine Besylate | 621 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 560 | 156 |
| Losartan Potassium | Losartan Potassium | 337 | 93 |
| Lisinopril | Lisinopril | 326 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 321 | 108 |
| Metformin Hcl | Metformin Hcl | 252 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 63 |
| Gabapentin | Gabapentin | 207 | 69 |
| Alendronate Sodium | Alendronate Sodium | 202 | 64 |
| Famotidine | Famotidine | 182 | 53 |
| Trazodone Hcl | Trazodone Hcl | 172 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 48 |
| Montelukast Sodium | Montelukast Sodium | 150 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 149 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 40 |
| Jardiance | Empagliflozin | 137 | 33 |
| Simvastatin | Simvastatin | 133 | 35 |
| Sertraline Hcl | Sertraline Hcl | 132 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 44 |
| Omeprazole | Omeprazole | 129 | 36 |
| Glipizide | Glipizide | 121 | 33 |
| Bupropion Xl | Bupropion Hcl | 116 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 31 |
| Carvedilol | Carvedilol | 108 | 31 |
| Mounjaro | Tirzepatide | 105 | 20 |
| Meloxicam | Meloxicam | 91 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 28 |
| Furosemide | Furosemide | 89 | 39 |
| Metformin Hcl Er | Metformin Hcl | 89 | 21 |
| Ozempic | Semaglutide | 89 | 19 |
| Prednisone | Prednisone | 89 | 71 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Azithromycin | Azithromycin | 75 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 22 |
| Alprazolam | Alprazolam | 73 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 34 |
| Potassium Chloride | Potassium Chloride | 71 | 28 |
| Allopurinol | Allopurinol | 67 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 16 |
| Clonazepam | Clonazepam | 62 | 23 |
| Methylprednisolone | Methylprednisolone | 59 | 55 |
| Trulicity | Dulaglutide | 59 | 14 |
| Cephalexin | Cephalexin | 58 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 12 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Meclizine Hcl | Meclizine Hcl | 51 | 22 |
| Glipizide Er | Glipizide | 50 | 15 |
| Pregabalin | Pregabalin | 50 | 16 |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 47 | suppressed |
| Myrbetriq | Mirabegron | 46 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 19 |
| Mirtazapine | Mirtazapine | 42 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 37 |
| Lorazepam | Lorazepam | 38 | 12 |
| Atenolol | Atenolol | 37 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 24 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 12 |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Chlorthalidone | Chlorthalidone | 34 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 12 |
| Baclofen | Baclofen | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 15 |
| Eliquis | Apixaban | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Indomethacin | Indomethacin | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.28 · 7 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, JARDIANCE, NEXLETOL, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error